We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.16 | 0.58% | 27.86 | 27.905 | 27.52 | 27.86 | 60,567,753 | 00:59:06 |
By Colin Kellaher
Pfizer Inc. (PFE) Tuesday said a phase 3 investigational study of Xeljanz in children and adolescents with juvenile idiopathic arthritis met its primary endpoint.
The New York drug maker said the occurrence of disease flare in patients with polyarticular juvenile idiopathic arthritis treated with Xeljanz was significantly lower than patients treated with placebo at week 44.
Pfizer said it plans to file for U.S. Food and Drug Administration approval of Xeljanz in juvenile idiopathic arthritis in 2020.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 12, 2019 07:14 ET (12:14 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions